scholarly journals Safety Findings in Pediatric Patients During Long‐Term Treatment With Teduglutide for Short Bowel Syndrome–Associated Intestinal Failure: Pooled Analysis of Four Clinical Studies

2020 ◽  
Author(s):  
Susan Hill ◽  
Beth A. Carter ◽  
Valeria Cohran ◽  
Simon Horslen ◽  
Stuart S. Kaufman ◽  
...  
Keyword(s):  
Short Bowel Syndrome ◽  
Clinical Studies ◽  
Pediatric Patients ◽  
Intestinal Failure ◽  
Pooled Analysis ◽  
Term Treatment ◽  
Short Bowel ◽  
Long Term Treatment

scholarly journals The Long-Term Treatment of Short Bowel Syndrome

2016 ◽  
Vol 2 ◽  
pp. e6
Author(s):  
Samantha McKenzie Stancu ◽  
◽  
Catalin Gabriel Cirstoveanu ◽  
Keyword(s):  
Short Bowel Syndrome ◽  
Term Treatment ◽  
Short Bowel ◽  
Long Term Treatment

Neonatal and Pediatric Parenteral Nutrition

2012 ◽  
Vol 23 (4) ◽  
pp. 451-464 ◽  
Author(s):  
Anne Gargasz
Keyword(s):  
Parenteral Nutrition ◽  
Short Bowel Syndrome ◽  
Pediatric Patients ◽  
Intestinal Failure ◽  
Nutritional Requirements ◽  
Gastrointestinal Fistula ◽  
Short Bowel ◽  
Therapeutic Modalities ◽  
The 1960S

Parenteral nutrition is one of the most important therapeutic modalities invented in the last several decades. Since its introduction in the 1960s, this modality has saved thousands of lives by providing nutrients parenterally to sustain growth in premature neonates with severe intestinal immaturity and other pediatric patients with intestinal failure, such as a gastrointestinal fistula or short bowel syndrome. Although parenteral nutrition can be a lifesaving treatment, it is not benign. Many complications can result from either short- or long-term usage. This review discusses the nutritional requirements, common complications, medication additives, and special considerations for pediatric patients requiring parenteral nutrition.

scholarly journals Electrospun Orodispersible Films of Isoniazid for Pediatric Tuberculosis Treatment

Pharmaceutics ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 470 ◽  
Author(s):  
Konstantina Chachlioutaki ◽  
Emmanouil K. Tzimtzimis ◽  
Dimitrios Tzetzis ◽  
Ming-Wei Chang ◽  
Zeeshan Ahmad ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Drug Loading ◽  
Term Treatment ◽  
Adherence To Treatment ◽  
Disintegration Time ◽  
Orodispersible Films ◽  
Long Term Treatment ◽  
Pediatric Patient Population ◽  
Pediatric Tuberculosis

Child-appropriate dosage forms are critical in promoting adherence and effective pharmacotherapy in pediatric patients, especially those undergoing long-term treatment in low-resource settings. The present study aimed to develop orodispersible films (ODFs) for isoniazid administration to children exposed to tuberculosis. The ODFs were produced from the aqueous solutions of natural and semi-synthetic polymer blends using electrospinning. The spinning solutions and the resulting fibers were physicochemically characterized, and the disintegration time and isoniazid release from the ODFs were assessed in simulated salivary fluid. The ODFs comprised of nanofibers with adequate thermal stability and possible drug amorphization. Film disintegration occurred instantly upon contact with simulated salivary fluid within less than 15 s, and isoniazid release from the ODFs in the same medium followed after the disintegration profiles, achieving rapid and total drug release within less than 60 s. The ease of administration and favorable drug loading and release properties of the ODFs may provide a dosage form able to facilitate proper adherence to treatment within the pediatric patient population.

scholarly journals Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24‐Week, Phase III Study

2019 ◽  
Vol 44 (4) ◽  
pp. 621-631 ◽  
Author(s):  
Samuel A. Kocoshis ◽  
Russell J. Merritt ◽  
Susan Hill ◽  
Susan Protheroe ◽  
Beth A. Carter ◽  
...  
Keyword(s):  
Short Bowel Syndrome ◽  
Pediatric Patients ◽  
Intestinal Failure ◽  
Phase Iii ◽  
Safety And Efficacy ◽  
Short Bowel ◽  
Phase Iii Study

scholarly journals Attention deficit and hyperactivity disorder in people with epilepsy: diagnosis and implications to the treatment

2010 ◽  
Vol 68 (1) ◽  
pp. 107-114 ◽  
Author(s):  
Julio A.S. Koneski ◽  
Erasmo B. Casella
Keyword(s):  
Adverse Effects ◽  
Attention Deficit ◽  
Clinical Studies ◽  
Social Life ◽  
Term Treatment ◽  
Hyperactivity Disorder ◽  
The Social ◽  
Long Term Treatment ◽  
Epilepsy Diagnosis

The association between attention deficit and hyperactivity disorder (ADHD) and epilepsy can cause significant impact on the social life of affected individuals and their families. Clinical studies suggest that 30-40% of people with epilepsy also have ADHD. There are no studies which demonstrate that short or long-term treatment with methylphenidate increases the risk of seizures. Some studies attempt to relate drug interactions between methylphenidate and antiepileptic drugs, but adverse effects of methylphenidate have not been shown clearly. This review presents some neurobiological and physiopathogenic aspects, common to ADHD and epilepsy, from recent research studies, related to pharmacology, neuroimaging and electroencephalography. Possible risk of occurrence of seizures associated with the use of methylphenidate are also discussed.

scholarly journals Pediatric Atopic Dermatitis: Update on the Treatment Options

2020 ◽  
Vol 25 (4) ◽  
pp. 60-62
Author(s):  
Corina Adelina Zah ◽  
Andreea Emiliana Toporău ◽  
Paul Grama
Keyword(s):  
Atopic Dermatitis ◽  
Chronic Treatment ◽  
Pediatric Patients ◽  
Treatment Options ◽  
Chronic Inflammatory Disease ◽  
Term Treatment ◽  
Phosphodiesterase 4 ◽  
Systemic Corticosteroids ◽  
Long Term Treatment

Abstract Atopic dermatitis (AD) is a chronic inflammatory disease characterized by skin dryness, pruritus and eczematous lesions with various periods of relapse. Symptomatology can appear in childhood and can persist in adulthood. Chronic treatment is required with corticosteroids being the standard options. The side effects of this type of long-term treatment represent a major concern for the pediatric patients. This review aims to give an update of the options used for treatment, apart from the systemic corticosteroids. Mild-to-moderate AD had a good response to creams containing fig and oatmeal extracts and inhibitors of phosphodiesterase-4 (crisaborole). In cases of severe AD, future treatment options could include monoclonal antibodies such as omalizumab and dupilumab

scholarly journals Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice

2021 ◽  
Vol 5 (19) ◽  
pp. 3799-3806
Author(s):  
Xiaoling Cheng ◽  
LingLing Fu ◽  
Jingyao Ma ◽  
Hao Gu ◽  
Zhenping Chen ◽  
...  
Keyword(s):  
Adverse Events ◽  
Pediatric Patients ◽  
Complete Response ◽  
Term Treatment ◽  
Serious Adverse Events ◽  
Platelet Counts ◽  
Chronic Itp ◽  
Long Term Treatment ◽  
Concomitant Medications

Abstract Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated thrombocytopenia and risk of hemorrhage. Treatment with eltrombopag increases and maintains hemostatic platelet counts; however, to date, long-term data are lacking on the outcome of children with ITP who are treated with eltrombopag. This prospective, observational, longitudinal cohort study evaluated the efficacy and safety of eltrombopag in pediatric patients with persistent or chronic ITP. For the 116 pediatric patients enrolled, duration of eltrombopag treatment was at least 3 months. Median effective dose was 25 mg/day, 50 mg/day, and 50 mg/day, respectively, for children age 5 years or younger, 6 to 11 years, or 12 years or older. In all, 89 patients (76.7%) achieved overall response, 53 (45.7%) achieved complete response, and 36 (31.0%) achieved response. Median platelet counts increased by week 1 and were sustained throughout the treatment period. During treatment with eltrombopag, the proportion of patients with grade 1 to 4 bleeding symptoms decreased from 83.61% at baseline to 9.88% at 6 months when only grade 1 was reported. Forty-three patients (37.1%) reported using concomitant medications at study entry, which was reduced to 1 patient (2.5%) who needed concomitant medications at 12 months. All adverse events were grade 1 or 2 according to Common Terminology Criteria for Adverse Events. No serious adverse events, cataracts, malignancies, or thromboses were reported during the study. Long-term treatment with eltrombopag was generally safe, well tolerated, and effective in maintaining platelet counts and reducing bleeding in most pediatric patients with persistent or chronic ITP. Combined with future studies, these findings will help establish how eltrombopag should best be used in the management of pediatric patients with East Asian ancestry.

Sign in / Sign up

Export Citation Format

Share Document